How past dengue infection or vaccination shapes T cell immunity
Official title: Project 3: Immunological imprinting of T cell responses following dengue virus natural infections and live attenuated dengue virus vaccination
Funded at University of California Berkeley · NIH-11111758 · Data updated 2026-11-12
This project looks at how previous dengue infections or a weakened dengue vaccine change T cells in children and others exposed to dengue.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | July 29, 2015 |
| Project end | July 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $251,393 |
| NIH project number | 2P01AI106695-11 |
| Project ID | NIH-11111758 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children (especially ages 0–11) who have had a prior dengue infection or who received a live attenuated dengue vaccine and who are enrolled in or willing to join a dengue cohort.
✕Less likely to help
People without prior dengue exposure or anyone needing immediate treatment for acute dengue are unlikely to get direct benefit from this immunology-focused project.
What this research studies
Researchers will use blood samples collected over time from children in dengue studies to measure dengue-specific T cells. They will map which parts of the virus these T cells recognize and how many different T cell receptors are involved. The team will compare responses after a second infection with a different dengue type or after receiving a live attenuated dengue vaccine. The goal is to see whether prior exposures make T cell responses broader or more focused and how that relates to protection or worse illness.
Why it matters
Potential benefit: Findings could help design safer, more effective dengue vaccines and predict who is at higher risk for severe dengue.
How similar studies have gone: Previous studies have identified dengue T cell targets and vaccine responses, but how prior infections imprint later T cell responses is not yet fully understood.
Where this research is happening
-
University of California Berkeley
Berkeley, United States Active
Researchers
- Principal investigator: Weiskopf, Daniela — University of California Berkeley
- Study coordinator: Weiskopf, Daniela
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
How the immune system responds to dengue vaccines and infection
This project compares immune reactions in people given different dengue vaccine formulations to find why one vaccine fully prevented DENV-2 infection while another did not.
-
How prior dengue infections shape T cell responses after a new infection or vaccine
This project looks at how a person’s existing dengue immunity affects their body's T cell response when exposed to a different dengue serotype or a live dengue vaccine, with a focus on kids and how this influences protection and safety.
-
Protective immunity after dengue infections and vaccination
Researchers are studying how our immune system remembers dengue and how vaccines influence that protection, aiming to spot clues that predict who remains protected or at risk after infection or vaccination.
-
Dengue vaccine-B cell and T cell responses linked to protection after controlled dengue infection
A Johns Hopkins-led study will look at how the body’s B and T cells respond to dengue vaccines and how these responses relate to protection against dengue infection in people who participate in a controlled infection model.
-
How long dengue vaccine protection lasts in areas where dengue is common
This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.